Patents by Inventor Ki-won Jo
Ki-won Jo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957005Abstract: A display device includes: a substrate; scan lines extending in a first direction, and arranged along a second direction crossing the first direction on the substrate; data lines extending in the second direction, and arranged along the first direction on the substrate; a display area including pixels connected to the scan lines and the data lines; and a non-display area around the display area, and including compensation capacitors connected to some scan lines from among the scan lines. A sum of a capacitance of q odd scan lines or q even scan lines that are adjacent to each other from among the scan lines increases in the second direction, where q is a positive integer.Type: GrantFiled: July 23, 2020Date of Patent: April 9, 2024Assignee: Samsung Display Co., Ltd.Inventors: Seo Won Choe, Ki Wook Kim, Yang Wan Kim, Hyun Woong Kim, Eun Byul Jo
-
Patent number: 9631020Abstract: Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.Type: GrantFiled: June 4, 2012Date of Patent: April 25, 2017Assignees: Korea Research Institute of Bioscience and Biotechnology, Y-Biologics Inc.Inventors: Young Woo Park, Ki Won Jo, Chan Woong Park, Seok Ho Yoo, Myeoung Hee Jang, Hye Nan Kim, Seon Ha Yun, Kyu Won Cho, Mi Ra Park
-
Patent number: 9617304Abstract: The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of SEQ ID NO. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition. The present invention shows the effects of suppressing metastasis, infiltration, angiogenesis, and growth of cancer by specifically inhibiting c-Met endocytosis and effectively inhibiting HGF/c-Met signaling pathway associated with metastasis and growth of various types of cancer cells. Therefore, the present invention can be applied to an anticancer agent for various types of cancer.Type: GrantFiled: March 2, 2012Date of Patent: April 11, 2017Assignee: Korea Research Institute Of Bioscience And BiotechnologyInventors: Young Woo Park, Ki Won Jo, Kyu Won Cho, Ji Hyun Park, Soon Sil Hyun, Yun Jung Park
-
Patent number: 9364556Abstract: The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual.Type: GrantFiled: November 28, 2012Date of Patent: June 14, 2016Assignees: Korea Research Institute of Bioscience and Biotechnology, A&RT Co., Ltd.Inventors: Young Woo Park, Ki Won Jo, Sun Jeong Jo, Soon Sil Hyun, Jae Eun Park, Seok Ho Yoo, Myeoung Hee Jang, Hye Nan Kim, Chan Woong Park
-
Patent number: 9200058Abstract: The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (?) and IL-21. The composition containing the double antagonist to TNF-? and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.Type: GrantFiled: March 18, 2011Date of Patent: December 1, 2015Assignees: Korea Research Institute of Bioscience and Biotechnology, Industry-Academic Cooperation Foundation, the Catholic University of KoreaInventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Sun-Ha Yoon, Ji Hyun Park, Eun Jung Song, Jong-Ho Lee, Min Ji Seo, Sun Jung Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
-
Publication number: 20150110815Abstract: The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual.Type: ApplicationFiled: November 28, 2012Publication date: April 23, 2015Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, Ki Won Jo, Sun Jeong Jo, Soon Sil Hyun, Jae Eun Park, Seok Ho Yoo, Myeoung Hee Jang, Hye Nan Kim, Chan Woong Park
-
Patent number: 8916525Abstract: The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-? and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells.Type: GrantFiled: March 18, 2011Date of Patent: December 23, 2014Assignees: Korea Research Institute of Bioscience and Biotechnology, Industry-Academic Cooperation Foundation, The Catholic University of KoreaInventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Dong Jin Kim, Sun-Ha Yoon, Eun Jung Song, Eun Kyung Lee, Jin Mi Oh, Kyu Won Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
-
Publication number: 20140072558Abstract: The present invention relates to an activin receptor type II B (ACVR2B) inhibitor which comprises the delta-like 1 homolog (DLK1) extracellular water-soluble domain. More specifically, the present invention relates to an extracellular soluble domain of DLK1; fragments of the extracellular soluble domain of DLK1; mutants of the extracellular soluble domain of DLK1; a composition for suppressing ligand linkage with the ACVR2B receptor, which includes a fragment of the mutants as an active ingredient; and a pharmaceutical composition for prevention and treatment of diseases which comprises the same. The composition of the present invention competitively binds to the ACVR2B receptor and inhibits the binding of an ACVR2B ligand to the ACVR2B receptor, which inhibits protein signalling associated with such ligands, and will be useful for prevention and treatment of diseases associated therewith.Type: ApplicationFiled: April 3, 2012Publication date: March 13, 2014Applicants: ANTIBODY AND RECEPTOR THERAPEUTICS CO., LTD., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Young Woo Park, Ki Won Jo, Donghee Lee, Eun Kyung Lee, Seil Jang, Chan Woong Park, Dong-Jin Kim, Hye Nan Kim, Yun Jung Park, Jae Eun Park, Ji Hyun Park, Seok Ho Yoo, Myeoung Hee Jang
-
Publication number: 20140066375Abstract: The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of SEQ ID NO. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition. The present invention shows the effects of suppressing metastasis, infiltration, angiogenesis, and growth of cancer by specifically inhibiting c-Met endocytosis and effectively inhibiting HGF/c-Met signaling pathway associated with metastasis and growth of various types of cancer cells. Therefore, the present invention can be applied to an anticancer agent for various types of cancer.Type: ApplicationFiled: March 2, 2012Publication date: March 6, 2014Inventors: Young Woo Park, Ki Won Jo, Kyu Won Cho, Ji Hyun Park, Soon Sil Hyun, Yun Jung Park
-
Publication number: 20130022642Abstract: The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (?) and IL-21. The composition containing the double antagonist to TNF-? and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.Type: ApplicationFiled: March 18, 2011Publication date: January 24, 2013Applicants: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, THE CATHOLIC UNIVERSITY OF KOREA, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Sun-Ha Yoon, Ji Hyun Park, Eun Jung Song, Jong-Ho Lee, Min Ji Seo, Sun Jung Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
-
Publication number: 20130017226Abstract: The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-? and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells.Type: ApplicationFiled: March 18, 2011Publication date: January 17, 2013Applicants: Industry-Academic Cooperation Foundation, The Catholic University of Korea, Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Dong Ji Kim, Sun-Ha Yoon, Eun Jung Song, Eun Kyung Lee, Jin Mi Oh, Kyu Won Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
-
Publication number: 20040002862Abstract: A voice recognition device including dedicated arithmetic calculating modules for arithmetic operations that are more frequently required among arithmetic operations necessary for voice recognition, an observation probability calculating device for calculating probabilities that each of the phonemes of a pre-selected word can be observed upon voice recognition, a complex Fast Fourier Transform (FFT) calculation device and method of calculating a complex FFT of complex data, a cache, and a cache controlling method are provided. The arithmetic modules interpret commands received from a receiver and perform operations indicated by the commands.Type: ApplicationFiled: May 30, 2003Publication date: January 1, 2004Applicant: Samsung Electronics Co., Ltd.Inventors: Jong-ho Kim, Hyun-woo Park, Tae-su Kim, Mi-jung Noh, Byung-ho Min, Ki-won Jo, Sung-hwan Jo, Seung-hwan Lee, Jin-won Jeong, Ho-rang Jang, Sun-hee Park, Keun-cheol Hong, Sung-jae Kim
-
Patent number: 6542002Abstract: A hybrid power supply circuit for supplying a power to a logic circuit performing a digital logic process and for controlling the charging/discharging of the logic circuit. The power supply circuit has an adiabatic power supply portion for charging/discharging the logic circuit in such a manner to suppress a sudden current change during initial time after the input signal changes, and a CMOS power supply portion for quickly charging/discharging the logic circuit to supply power level/ground level after the charging/discharging by the adiabatic power supply portion. The energy consumption of the circuit decreases even in a digital system having a plurality of logic circuits.Type: GrantFiled: February 11, 2002Date of Patent: April 1, 2003Assignee: Samsung Electronics Co., Ltd.Inventors: Ho-rang Jang, Ki-won Jo
-
Publication number: 20020158660Abstract: A hybrid power supply circuit for supplying a power to a logic circuit performing a digital logic process and for controlling the charging/discharging of the logic circuit. The power supply circuit has an adiabatic power supply portion for charging/discharging the logic circuit in such a manner to suppress a sudden current change during initial time after the input signal changes, and a CMOS power supply portion for quickly charging/discharging the logic circuit to supply power level/ground level after the charging/discharging by the adiabatic power supply portion. The energy consumption of the circuit decreases even in a digital system having a plurality of logic circuits.Type: ApplicationFiled: February 11, 2002Publication date: October 31, 2002Applicant: Samsung Electronics Co., Ltd.Inventors: Ho-rang Jang, Ki-won Jo